| アブストラクト | PURPOSE: To report the characteristics of uveitis cases occurring while on biologic therapy or disease-modifying antirheumatic drugs (DMARDs) reported to the French national pharmacovigilance database. METHODS: All the uveitis cases occurring in patients with chronic rheumatologic diseases, chronic inflammatory intestinal diseases or connective tissue diseases, while treated with DMARDs and/or biologic therapies between 2000 and 2015 and reported to the French National Pharmacovigilance Database were collected. RESULTS: During the study period, 32 cases of uveitis were reported (15 men, 17 women). Two patients were treated with one DMARD alone, 24 with biologic therapy alone, and six with both treatments. Anterior uveitis was diagnosed in 19 patients (8 cases were bilateral); intermediate uveitis was found (unilaterally) in one patient; posterior and diffuse uveitis occurred in 5 and 2 cases respectively. Five cases were inconclusive with regard to the anatomical type of uveitis. The uveitis was of infectious origin in 5 cases: 2 toxoplasmosis, 2 herpes virus and 1 tuberculosis. In the 27 other cases, it was not possible to state whether the uveitis was associated with the underlying disease (uncontrolled) or a side effect of the biologic/DMARD treatments. The occurrence of the uveitis led to 9 switches in biologic therapy and 13 discontinuations of treatment (8 complete discontinuations, 5 discontinuations only until uveitis remission was obtained). In 4 cases, the treatments were not modified. The database does not specify the ultimate course or rheumatologic disease activity at the time of the uveitis. CONCLUSIONS: The presence of uveitis while on biologic therapy must not be taken to indicate a therapeutic failure, especially if the ocular manifestation is isolated. In the case of uveitis occurring in patients treated with biologic therapies and/or DMARDs, infectious complications should be ruled out. |
|---|
| ジャーナル名 | Journal francais d'ophtalmologie |
|---|
| Pubmed追加日 | 2018/4/17 |
|---|
| 投稿者 | Cabane, L; Baillif, S; Baldin, B; Breuil, V; Euller-Ziegler, L; Tieulie, N |
|---|
| 組織名 | Service de rhumatologie, hopital Pasteur 2, CHU de Nice, 30, voie Romaine, CS;51069, 06001 Nice cedex 1, France.;Service d'ophtalmologie, hopital Pasteur 2, CHU de Nice, 30, voie Romaine, CS;Service de pharmacovigilance, hopital de Cimiez, CHU de Nice, 4, avenue;Reine-Victoria, 06003 Nice, France.;51069, 06001 Nice cedex 1, France. Electronic address: tieulie.n@chu-nice.fr. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/29656829/ |
|---|
